Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01
2018 · Annals of Surgical Oncology · 336 citations
https://doi.org/10.1245/s10434-018-6494-6
A
Atilla Soran
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
257
Papers
8.1K
Citations
40
h-index
92
i10-index
Atilla Soran is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Breast Cancer Treatment Studies & Breast Lesions and Carcinomas & Breast Implant and Reconstruction. The author has an h-index of 40, co-authored 219 publications.
ORCID: 0000-0002-3398-7230Papers by this author
worksMRI Staging After Neoadjuvant Chemotherapy for Breast Cancer: Does Tumor Biology Affect Accuracy?
2011 · Annals of Surgical Oncology · 122 citations
https://doi.org/10.1245/s10434-011-1912-z
Low Estrogen Receptor (ER)–Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy
2018 · American Journal of Clinical Pathology · 76 citations
https://doi.org/10.1093/ajcp/aqy028
Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer
2010 · Modern Pathology · 56 citations
https://doi.org/10.1038/modpathol.2010.209
Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors
2017 · Modern Pathology · 39 citations
https://doi.org/10.1038/modpathol.2017.41
The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer
2016 · Breast Disease · 38 citations
https://doi.org/10.3233/bd-150199
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat